Glaspimod (SK&F 107647) is a synthetic hematoregulatory peptide that shares biological and/or modulatory activities with natural hematopoietic cytokines. The peptide has been tested in vitro and in vivo for hematopoietic effects (involvement in production of cellular blood components). In vitro, glaspimod has no direct colony-stimulating activity (CSA), In vivo, injection of the compound results in an increase in serum CSA (maximal at 6 hours after injection). With repeated administration, significant increases in absolute numbers of granulocyte-macrophage (CFU-GM), erythroid (BFU-E), and multipotential (CFU-GEMM) progenitor cells can be measured. Pharmacokinetic effects of glasmipod have been studied in patients with adenocarcinoma and were not amenable to standard therapy.

LANCOVUTIDE, also known as duramycin, is a 19-amino-acid tetracyclic peptide antibiotic. It is in clinical development for the treatment of cystic fibrosis (CF). It activates an alternative chloride channel in lung epithelial cells by elevating intracellular calcium levels, and may potentially compensate for CF transmembrane conductance regulator deficiency in the airway epithelium and increase the volume of the airway surface liquid.

Basifungin, previously known as LY 295337 or aureuobacidin A, is an antifungal agent that inhibits phosphorylceramide synthase. The development of basifungin against mycoses was discontinued.

(3,5-DIBROMO-4-HYDROXYPHENYL)(2,3-DIHYDRO-4H-PYRIDO[4,3-B][1,4]OXAZIN-4-YL)METHANONE (UR-1102/URC-1022) is currently under development for the management of hyperuricaemia in gout. It is a selective URAT1 inhibitor with Ki of 57 nM showing higher uricosuric effects than benzbromarone in monkeys with potentially lower mitochondrial toxicity which is supposed to be related to hepatotoxicity. There is also a probable inhibition of OAT1 and OAT3. UR-1102, which is derived from the chemical structure of benzbromarone, was designed to not only improve URAT1 selectivity and solubility but also to avoid the hepatic toxicity concern of benzbromarone, which is known to be associated with hepatic injury and to have the potential to cause fulminant hepatitis in humans. The results of two phase II trials presented at the 2017 ACR meeting suggested a high potency for reducing SU levels with a good safety profile on a short follow-up. No phase III trial has been registered so far.